Diffuse Intrinsic Pontine Glioma Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Diffuse Intrinsic Pontine Glioma Market

DelveInsight’s Diffuse Intrinsic Pontine Glioma (DIPG) Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Diffuse Intrinsic Pontine Glioma (DIPG), historical and forecasted epidemiology as well as the Diffuse Intrinsic Pontine Glioma (DIPG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Diffuse Intrinsic Pontine Glioma (DIPG) market report provides current treatment practices, emerging drugs, Diffuse Intrinsic Pontine Glioma (DIPG) market share of the individual therapies, current and forecasted Diffuse Intrinsic Pontine Glioma (DIPG) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Diffuse Intrinsic Pontine Glioma (DIPG) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Diffuse Intrinsic Pontine Glioma (DIPG) market.

Some of the key facts of the Diffuse Intrinsic Pontine Glioma  Market:

• The incident population of pediatric DIPG and adult DIPG in the United States was 398 cases and 429 cases, respectively, in 2020, which is anticipated to increase in the forecast period 2021-2030. While the incident population of DIPG with H3K27 Mutation in the United States was 318 children and 214 in adults in 2020.

• A German study conducted by  Karremann, et al. titled “Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location”, wherein 85 centrally diffuse gliomas on midline locations patients were enrolled in the nationwide pediatric German HIT-HGG registry. Researchers found that approximately 56 H3.3 K27M-mutant tumors (66%), 6 H3.1 K27M-mutant tumors (7%), and 23 H3-wildtype tumors (27%) were present.

Got queries? Click here to know more about the Diffuse Intrinsic Pontine Glioma  Market Landscape 

Diffuse Intrinsic Pontine Glioma  Overview 

According to the National Cancer Institute (NCI), Diffuse Intrinsic Pontine Glioma (DIPG: also known as Diffuse Midline Glioma (DMG)) are primary central nervous system (CNS) tumors. This means they begin in the brain or spinal cord. It is a rare subtype of glial tumor and is considered a Grade IV tumor. Diffuse Intrinsic Pontine Glioma (DIPG) harboring the H3 K27M are lethal high-grade pediatric brain tumors that are inoperable and without a cure. DIPGs are all Grade IV tumors, which means they are malignant (cancerous) and fast-growing.

DIPG tumors grow quickly, therefore the symptoms can develop over the course of days or weeks. These can lead to common symptoms such as abnormalities in eye movements, weakness of one side of the face, numbness, difficulty with balance, headaches, nausea, etc.

With advances in DNA sequencing and understanding of tumor genetics, these tumors are increasingly biopsied and analyzed for genetic markers. In fact, DMG is a new classification group recognizing that tumors with these mutations are similar, and thus may respond similarly to certain treatment options.

Diffuse Intrinsic Pontine Glioma  Epidemiological Insight:

• H3 K27 mutations, most commonly in H3F3A, are common in Diffuse Intrinsic Pontine Glioma (DIPG). The exact frequency of these mutations in adults with gliomas in the midline location is unknown. Despite numerous clinical trials, the prognosis remains poor, with a median survival of ~1 year from diagnosis.

• As per a study by Himes et al. titled, “Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges”, primary pediatric brain tumors are rare entities, with an incidence of around 2,200 cases annually. DMG, which makes up approximately 20% of these primary pediatric primary brain tumors, carries among the urgent prognosis

• According to St. Jude Children’s Research Hospital, US, about 10–20% of all childhood brain tumors are DIPG or brainstem gliomas. They are more common in children between the ages of 5 and 10 years but can occur at any age in childhood. Though rarer, they can also occur in adults.

Diffuse Intrinsic Pontine Glioma  Epidemiological Segmentation

• Diffuse Intrinsic Pontine Glioma Incident cases of Primary Brain Tumor 
• Diffuse Intrinsic Pontine Glioma Total incident cases
• Diffuse Intrinsic Pontine Glioma Age specific Incident cases
• Diffuse Intrinsic Pontine Glioma Diagnosed and Treatable cases

Diffuse Intrinsic Pontine Glioma  Market Outlook 

The Diffuse Intrinsic Pontine Glioma (DIPG) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Diffuse Intrinsic Pontine Glioma (DIPG) market trends by analyzing the impact of current Diffuse Intrinsic Pontine Glioma (DIPG) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Diffuse Intrinsic Pontine Glioma (DIPG) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diffuse Intrinsic Pontine Glioma (DIPG) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Diffuse Intrinsic Pontine Glioma (DIPG) market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @Diffuse Intrinsic Pontine Glioma  Market Landscape

Diffuse Intrinsic Pontine Glioma Key Companies  

• Oncoceutics
• Bexion Pharma
• DNAtrix
• Kazia Therapeutics 
• And many more 

Diffuse Intrinsic Pontine Glioma Key Therapies

• ONC201
• BXQ-350
• DNX-2401
• Paxalisib
• And many more

Table of Contents

• Key Insights 
• Report Introduction 
• Executive Summary of Diffuse Intrinsic Pontine Glioma  Market 
• Disease Background and Overview
• Epidemiology and patient population
• The United States 
• EU 5
• Diffuse Intrinsic Pontine Glioma  Market  Emerging Therapies
• Diffuse Intrinsic Pontine Glioma  Market Outlook
•  Market Access and Reimbursement of Therapies
•  Appendix
• Diffuse Intrinsic Pontine Glioma  Market Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Click here to read more about Diffuse Intrinsic Pontine Glioma  Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com